Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LCP-tacrolimus + mycophenolate mofetil
- Development stage
- Phase 4
- Lead developer
- Veloxis Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination involves **LCP-tacrolimus** (a once-daily formulation of tacrolimus) and **mycophenolate mofetil** (MMF), both used as immunosuppressants to prevent organ rejection in transplant patients. Tacrolimus is a calcineurin inhibitor that suppresses the immune system by inhibiting the production of interleukin-2, while MMF inhibits inosine monophosphate dehydrogenase, reducing lymphocyte proliferation. This combination is often used in kidney transplantation.
02
Targets
CN (Calcineurin)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on LCP-tacrolimus + mycophenolate mofetil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LCP-tacrolimus + mycophenolate mofetil.